Ambeed.cn

首页 / 抑制剂/激动剂 / / Calcium Channel / Nicardipine HCl/盐酸尼卡地平

Nicardipine HCl/盐酸尼卡地平 {[allProObj[0].p_purity_real_show]}

货号:A570738 同义名: YC-93; Nicardipine (hydrochloride)

Nicardipine HCl is a calcium channel blocker that has been widely used to control blood pressure in severe hypertension following events such as ischemic stroke, traumatic brain injury, and intracerebral hemorrhage.

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Nicardipine HCl/盐酸尼卡地平 化学结构 CAS号:54527-84-3
Nicardipine HCl/盐酸尼卡地平 化学结构
CAS号:54527-84-3
Nicardipine HCl/盐酸尼卡地平 3D分子结构
CAS号:54527-84-3
Nicardipine HCl/盐酸尼卡地平 化学结构 CAS号:54527-84-3
Nicardipine HCl/盐酸尼卡地平 3D分子结构 CAS号:54527-84-3
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 1周 咨询 - +
购物车0 收藏 询单

Nicardipine HCl/盐酸尼卡地平 纯度/质量文件 产品仅供科研

货号:A570738 标准纯度: {[allProObj[0].p_purity_real_show]}
批次查询: 批次纯度:

全球学术期刊中引用的产品

更多 >
产品名称 Ca2+ channel-like protein Calcium Channel Cav 2.2 其他靶点 纯度
CDC25B-IN-2 Akt 99%+
Clevidipine 97%
Verapamil HCl 99%
Amlodipine 99%
Amlodipine maleate 98%
(+)-cis-Diltiazem HCl 99%
Zegocractin ++

Orai1/STIM1-mediated Ca2+ currents, IC50: 120 nM

99%+
Tanshinone IIA sulfonate sodium 98%
Ulixacaltamide ++

hCaV3.1, IC50: 50 nM

hCaV3.2, IC50: 110 nM

99%+
Dronedarone HCl 95%
Nitrendipine +

Calcium channel, IC50: 95 nM

98%
Efonidipine HCl monoethanolate 98%
Cinnarizine 98%
SEA0400 ++

NCX, IC50: 33 nM

ROS,ERK,p38 MAPK 99%+
Fasudil HCl PKA,Rho 98%
ML-9 Akt,MLCK 99%+
Flunarizine 2HCl +

Calcium channel, Ki: 68 nM

95%
Lomerizine 2HCl 98%
Efonidipine 98%
Levamlodipine 98%
Nisoldipine ++

L-type Cav1.2, IC50: 10 nM

97%
Isradipine 98%
Lacidipine 98%
Lercanidipine 99%
Loureirin B Potassium Channel 99%+
Tetracaine HCl 98%
Manidipine +++

Calcium channel, IC50: 2.6 nM

99%
Manidipine Dihydrochlorid +++

Calcium channel, IC50: 2.6 nM

98%
Nicardipine 99%
Wilforgine 98+%
Econazole 99%+
Ginsenoside Rd NF-κB 98%
Fendiline HCl 98+%
Mesaconitine 98%
Tetrandrine 95%
Nifedipine 95%
Nilvadipine ++++

Calcium channel, IC50: 0.03 nM

98%
Barnidipine ++++

[3H]nitrendipine, Ki: 0.21 nM

95+%
Azelnidipine 97%
Levetiracetam 98%
Nimodipine 95%
Benidipine HCl 98%
Pinaverium bromide 98%
Pranidipine 99%
NP118809 +

N-type Ca2+ channel, IC50: 0.11 μM

L-type calcium channel, IC50: 12.2 μM

98%
Amlodipine Besylate +++

Calcium channel, IC50: 1.9 nM

97%
Cilnidipine 99%
Cinepazide Maleate 99% (HPLC)
Terfenadine 98%
YM-58483 99%+
Ranolazine 98%
Praeruptorin A p38 MAPK,Akt 98%
Ranolazine 2HCl 98%
Felodipine ++++

L-type calcium channel, IC50: 0.15 nM

98%
PD173212 +++

N-type Ca2+ channel, IC50: 36 nM

98%
Levamlodipine besylate 97%
Carboxyamidotriazole Orotate 98%
IGS-1.76 98+%
WH-4-023 ++++

Cav 2.2, IC50: 0.001 μM

++++

Cav 2.2, IC50: 0.001 μM

99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。

Nicardipine HCl/盐酸尼卡地平 生物活性

描述 Nicardipine hydrochloride (NC-HCl), a calcium channel blocker for the treatment of chronic stable angina and hypertension, seems to be a potential therapeutic transdermal system candidate, mainly due to its low dose, short half-life, and high first-pass metabolism[3]. Uterine activity was inhibited by all treatment regimens, but the most significant inhibition was achieved by the higher dose of nicardipine, which nearly abolished all uterine activity in pregnant rabbit during induced preterm uterine contractions[4]. The L-type voltage-dependent Ca(2+) channels (L-VDCC) blocker, nicardipine, significantly inhibited ACh- (acetylcholine) and Ca(2+)-enhanced BSM (bronchial smooth muscles) contractions in guinea pigs infused with HCl[5]. In patients with moyamoya disease, nicardipine may have a beneficial effect on cerebral hemodynamics and may prevent ischemic sequelae by optimizing existing collateral circulation[6]. In rabbit, nicardipine-HCl decreased the spontaneous rate of the sinoatrial (SA) node and prolonged sinus recovery time, dose-dependently. The effective refractory period (ERP) and functional refractory period (FRP) of the atrioventricular (AV) node and AV conduction time (A-H interval) were also prolonged by nicardipine-HCl in a dose-dependent manner[7].

Nicardipine HCl/盐酸尼卡地平 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT02286089 Age-related Macular Degenerati... 展开 >>on 收起 << Phase 1 Phase 2 Recruiting December 2019 United States, California ... 展开 >> Retina Vitreous Associates Medical Group Recruiting Los Angeles, California, United States, 900211 Contact: Janet Kurokouchi, B.Sc.    310-289-2478 ext 1243    JKurokouchi@laretina.com    Contact: Gerard Aquino, B.Sc.    310-289-2478 ext 1225    GAquino@laretina.com    Principal Investigator: David Boyer, MD          Byers Eye Institute, Stanford School of Medicine Recruiting Palo Alto, California, United States, 94303 Contact: Lisa Greer, MBA    650-725-9184    lgreer7@stanford.edu    Principal Investigator: Diana Do, Prof.          Retinal Consultants Medical Group Recruiting Sacramento, California, United States, 95819 Contact: Erin Nickerman    916-453-5429    nickermane@retinalMD.com    Contact: Whitney Lewis    916-453-5429    lewisw@retinalmd.com    Principal Investigator: David Telander, MD          West Coast Retina Medical Group, Inc Recruiting San Francisco, California, United States, 94109 Contact: Kaitlin E. Miani, BA    415-972-4607    kmiani@westcoastretina.com    Contact: C.          Principal Investigator: Richard McDonald, MD          Israel Hadassah Ein Kerem University Hospital Recruiting Jerusalem, Israel, 91120 Contact: Devora Marks Ohana    972-2-6776324    dryamdstudy@gmail.com    Principal Investigator: Tareq Jaouni, MD          Rabin Medical Center Recruiting Petah Tikva, Israel Contact: Vivi Dagan    972-3-9377199    eyeclinic@clalit.org.il    Principal Investigator: Rita Ehrlich, MD          Kaplan Medical Center Recruiting Rehovot, Israel Contact: Michal Scwartzberg    972-8-9441691    kaplaneye1@gmail.com    Principal Investigator: Haia Morori-Katz, MD          Tel Aviv Souraski Medical Center Recruiting Tel Aviv, Israel, 91121 Contact: Sagit Bechor    03-6974361    sagitba@tlvmc.gov.il    Principal Investigator: Adiel Barak, MD, Prof. 收起 <<
NCT02725840 - Recruiting April 2021 United States, Florida ... 展开 >> Department of Radiation Oncology Davis Cancer Pavilion Recruiting Gainesville, Florida, United States, 32611 Contact: John M Lybarger, MPH    352-265-0680 ext 87829    lybarj@shands.ufl.edu    Principal Investigator: Walter O'Dell, PhD          Sub-Investigator: Karen Daily, DO          Sub-Investigator: Coy Heldermon, MD, PhD          Sub-Investigator: David Wymer, MD          Sub-Investigator: Fei Zou, PhD          Sub-Investigator: Paul Okunieff, MD          Sub-Investigator: Jorge Lascano, MD          University of Florida Health Proton Therapy Institute Recruiting Jacksonville, Florida, United States, 32206 Contact: Julie Bradley, MD    904-588-1800    jbradley@floridaproton.org    Sub-Investigator: Nancy Mendenhall, MD          Sub-Investigator: Christopher Klassen, MD, PhD          Sub-Investigator: Michael Rutenberg, MD          Sub-Investigator: Roi Dagan, MD, MS          Principal Investigator: Julie Bradley 收起 <<
NCT01893307 Head And Neck Cancer Phase 2 Phase 3 Recruiting August 2023 United States, Arizona ... 展开 >> Mayo Clinic - Arizona Recruiting Scottsdale, Arizona, United States, 85259 United States, California University of California at San Diego Recruiting La Jolla, California, United States, 92093 Contact: Loren Mell, MD          United States, Florida Florida Health Protocol Institute Recruiting West Palm Beach, Florida, United States, 33407 Contact: Roi Dagan, MD          United States, Illinois Northwestern Memorial Hospital Recruiting Chicago, Illinois, United States, 60611 Contact: John H. Han-Chang, MD          United States, Maryland University of Maryland Recruiting College Park, Maryland, United States, 20742 Contact: William Regine, MD          Contact: Charles Simone, MD          United States, Massachusetts Massachusetts General Hospital Recruiting Boston, Massachusetts, United States, 02114 Contact: Paul Busse, MD          United States, Minnesota Mayo Clinic Recruiting Rochester, Minnesota, United States, 55905 Contact: Robert Foote, MD          United States, New York Memorial-Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Nancy Y. Lee, MD          United States, Pennsylvania University of Pennsylvania Health System Recruiting Philadelphia, Pennsylvania, United States, 19104 Contact: Alexander Lin, MD          United States, Texas University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 United States, Washington University of Washington Recruiting Seattle, Washington, United States, 98105 Contact: Upendra Parvathaneni, MD 收起 <<

Nicardipine HCl/盐酸尼卡地平 参考文献

[1]Huang BR, Chang PC, et al. Anti-neuroinflammatory effects of the calcium channel blocker nicardipine on microglial cells: implications for neuroprotection. PLoS One. 2014 Mar 12;9(3):e91167.

[2]Gasior M, Kamiński R, et al. Influence of nicardipine, nimodipine and flunarizine on the anticonvulsant efficacy of antiepileptics against pentylenetetrazol in mice. J Neural Transm (Vienna). 1996;103(7):819-31.

[3]Aboofazeli R, Zia H, Needham TE. Transdermal delivery of nicardipine: an approach to in vitro permeation enhancement. Drug Deliv. 2002;9(4):239‐247

[4]Holbrook RH Jr, Lirette M, Katz M. Cardiovascular and tocolytic effects of nicardipine HCl in the pregnant rabbit: comparison with ritodrine HCl. Obstet Gynecol. 1987;69(1):83‐87

[5]Cheng YM, Cao AL, Zheng JP, et al. Airway hyperresponsiveness induced by repeated esophageal infusion of HCl in guinea pigs. Am J Respir Cell Mol Biol. 2014;51(5):701‐708

[6]Hosain SA, Hughes JT, Forem SL, Wisoff J, Fish I. Use of a calcium channel blocker (nicardipine HCl) in the treatment of childhood moyamoya disease. J Child Neurol. 1994;9(4):378‐380

[7]Tamamura T, Konishi T, Matsuda H, Kadoya M, Yokoyama S, Kawai C. Electrophysiological effects of nicardipine hydrochloride on the isolated sinoatrial and atrioventricular nodes of the rabbit. Jpn Circ J. 1983;47(7):817‐823

Nicardipine HCl/盐酸尼卡地平 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.94mL

0.39mL

0.19mL

9.69mL

1.94mL

0.97mL

19.38mL

3.88mL

1.94mL

Nicardipine HCl/盐酸尼卡地平 技术信息

CAS号54527-84-3
分子式C26H30ClN3O6
分子量 515.99
SMILES Code O=C(C1=C(C)NC(C)=C(C(OCCN(C)CC2=CC=CC=C2)=O)C1C3=CC=CC([N+]([O-])=O)=C3)OC.[H]Cl
MDL No. MFCD00057327
别名 YC-93; Nicardipine (hydrochloride); RS 69216; Nicardipine hydrochloride
运输蓝冰
InChI Key AIKVCUNQWYTVTO-UHFFFAOYSA-N
Pubchem ID 41114
存储条件

In solvent -20°C:3-6个月-80°C:12个月

Pure form Keep in dark place, inert atmosphere, 2-8°C

Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。